Your browser doesn't support javascript.
Antibody and B cell responses to SARS-CoV-2 infection and vaccination.
Röltgen, Katharina; Boyd, Scott D.
  • Röltgen K; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Boyd SD; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Sean N. Parker Center for Allergy & Asthma Research, Stanford, CA, USA. Electronic address: sboyd1@stanford.edu.
Cell Host Microbe ; 29(7): 1063-1075, 2021 07 14.
Article in English | MEDLINE | ID: covidwho-1272338
ABSTRACT
Antibodies, and the B cell and plasma cell populations responsible for their production, are key components of the human immune system's response to SARS-CoV-2, which has caused the coronavirus disease 2019 (COVID-19) pandemic. Here, we review findings addressing the nature of antibody responses against SARS-CoV-2 and their role in protecting from infection or modulating COVID-19 disease severity. In just over a year, much has been learned, and replicated in independent studies, about human immune responses to this pathogen, contributing to the development of effective vaccines. Nevertheless, important questions remain about the duration and effectiveness of antibody responses, differences between immunity derived from infection compared to vaccination, the cellular basis for serological findings, and the extent to which viral variants will escape from current immunity.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: B-Lymphocytes / Vaccination / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Host Microbe Journal subject: Microbiology Year: 2021 Document Type: Article Affiliation country: J.chom.2021.06.009

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: B-Lymphocytes / Vaccination / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Host Microbe Journal subject: Microbiology Year: 2021 Document Type: Article Affiliation country: J.chom.2021.06.009